Answers are grounded in this paper and cite their sources.
Prospective trial investigates a novel continuous glucose monitoring system in children, showing high performance and usability.
BACKGROUND: A proprietary continuous glucose monitoring (CGM) system that uses third-generation sensor technology has previously been shown to exhibit stable, single-digit mean absolute relative difference (MARD) and 15-day wear life in adults with diabetes. METHOD: This was a prospective, single-arm study of pediatric participants aged 2 to 17 years that were enrolled at 3 clinical centers. Participants wore 2 sensors, one on each side of the abdomen, and were randomized to assessment of device performance on days 1 and 2, days 7 to 9 or days 15 and 16. Device performance across a range of metrics was assessed by comparison with venous blood glucose values obtained using a laboratory reference device. Per-protocol results are reported for the sensor with the inferior MARD. RESULTS: The per-protocol set comprised 75 participants, of whom 16 were aged 2 to 5 years. The overall MARD was 8.89%, and MARDs at days 1 and 2, 7 to 9 and 15 and 16 were 8.65%, 8.70% and 9.30%, respectively. DTS error grid analyses showed that 100.0% of data pairs fell in clinically acceptable zones A+B. True alarm rates for hypoglycemia and hyperglycemia were high, at 98.6% and 98.8%, respectively. Mean sensor wear life was 14.4 days, and participant/guardian assessments of sensor usability revealed high satisfaction with respect to system assembly, sensor insertion and overall comfort. No device-related or skin-related adverse events were reported. CONCLUSIONS: In a pediatric population, the novel CGM system demonstrated accurate and stable performance across its 15-day wear life and showed high usability.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: